Evidence map›Paper›PMID 30641865›Full record

ReviewNutrients2019

Resveratrol and Its Human Metabolites-Effects on Metabolic Health and Obesity.

Margherita Springer, Sofia Moco

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07395921 (Effects of Resveratrol Supplementation on Inflammatory Biomarkers and Cardiometabolic Parameters in Community-dwelling Adults.), which is not on this map. Cited by 153 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
153citing papers in PubMed, 5 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07395921 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Effects of Resveratrol Supplementation on Inflammatory Biomarkers and Cardiometabolic Parameters in Community-dwelling Adults. (RESINCA-trial)

TypeinterventionalSponsorCenter for Research and Innovation Viña Concha y ToroRan2026 to 2026Enrolled75ConditionsInflammation Biomarkers, Cardiometabolic Health Indicators, Antioxidant Status, Inflammation, Antioxidant CapabilitiesArmsRES 120, RES 250, RES 500
3 · Its place in the literature

Who cites it

153 citing papers in PubMed, 5 syntheses or guidelines pooled it, 279 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Research Progress on the Quorum Sensing System ofPathogens (Basel, Switzerland) · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

93 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Margherita SpringerNestle Institute of Health Sciences, Nestle Research, EPFL Innovation Park, Building H, 1015 Lausanne, Switzerland. margherita.springer@rd.nestle.com.
Sofia MocoNestle Institute of Health Sciences, Nestle Research, EPFL Innovation Park, Building H, 1015 Lausanne, Switzerland. sofia.moco@rd.nestle.com.ORCID 0000-0001-8170-8876
Nestlé (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resveratrol is one of the most widely studied polyphenols and it has been assigned a plethora of metabolic effects with potential health benefits. Given its low bioavailability and extensive metabolism, clinical studies using resveratrol have not always replicated in vitro observations. In this review, we discuss human metabolism and biotransformation of resveratrol, and reported molecular mechanisms of action, within the context of metabolic health and obesity. Resveratrol has been described as mimicking caloric restriction, leading to improved exercise performance and insulin sensitivity (increasing energy expenditure), as well as having a body fat-lowering effect by inhibiting adipogenesis, and increasing lipid mobilization in adipose tissue. These multi-organ effects place resveratrol as an anti-obesity bioactive of potential therapeutic use.

Indexed as

AdiposityAnimalsEnergy MetabolismGastrointestinal MicrobiomeHumansInsulin ResistanceModels, AnimalObesityPhytoalexinsPolyphenolsResveratrolSesquiterpenesPhytoalexinsPolyphenolsResveratrolSesquiterpenesdiabetesmetabolic pathwaysmetabolismobesitypolyphenolsresveratrol

Identifiers

PMID30641865
PMCPMC6357128
OpenAlexW2911117569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.